HER2-negative metastatic breast cancer

May 14, 2018May 14, 2018

Study Discovers Mutations That Cause Resistance to Lynparza, Similar Therapies

News

Researchers have identified mutations in the poly (ADP-ribose) polymerase (PARP) gene that cause resistance to the cancer therapy Lynparza (olaparib) and other PARP inhibitors. These mutations could help physicians predict which cancer ... Read more

October 20, 2017October 20, 2017

FDA to Review Lynparza Extension for Certain Advanced Breast Cancer Patients

News

The U.S. Food and Drug Administration (FDA) will review AstraZeneca and Merck‘s application seeking the extension of Lynparza (olaparib) tablets for the treatment of HER-negative metastatic breast cancer patients whose ... Read more

March 9, 2016May 16, 2016

FDA Approves Combination Treatment of Faslodex/Ibrance for Certain Metastatic Breast Cancers

News

The U.S. Food and Drug Administration (FDA) has approved expanding the use of AstraZeneca’s breast cancer drug Faslodex (fulvestrant), in combination with Pfizer’s Ibrance (palbociclib), to treat advanced breast cancers (BC). The combination ... Read more

February 16, 2015February 16, 2015

FDA Approves Ibrance for Advanced Breast Cancer in Postmenopausal Women

Breast Cancer News, News

Pfizer, Inc. has been granted accelerated approval from the U.S. Food and Drug Administration for its drug Ibrance (palbociclib) for the treatment of advanced metastatic breast cancer. Ibrance is meant to treat postmenopausal ... Read more

October 14, 2014October 16, 2014

Pfizer’s Palbociclib Granted FDA Priority Review For ER+ Breast Cancer Treatment

News

Pfizer Inc. has announced that the New Drug Application (NDA) for palbociclib has been accepted for filing and granted Priority Review by the United States Food and Drug Administration (FDA). ... Read more

October 9, 2014October 9, 2014

Two Phase III Studies Evaluating Bevacizumab in Metastatic Breast Cancer Presented At ESMO

News

The results of two randomised phase III clinical trials in HER2-negative metastatic breast cancer were presented at the European Society for Medical Oncology (ESMO) 2014 meeting, Madrid, Spain. Dr. Joseph ... Read more